NEW YORK, Oct. 28, 2016 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE:ADPT) of the December 27, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Eastern District of Texas on behalf of all those who purchased Adeptus Class A common shares pursuant to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or common shares between April 23, 2015 and November 16, 2015 (the “Class Period”). The case, Oklahoma Law Enforcement Retirement System v. Adeptus Health Inc. et al, No. 6:16-cv-01243 was filed on October 27, 2016.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by engaging in potential predatory billing practices, particularly with respect to lower acuity level patients.
Specifically, on November 17, 2015, KUSA, an NBC-affiliated television station located in Denver, Colorado, aired a 9WANTS To Know investigative report about the billing practices at Adeptus Health's Colorado First Choice emergency rooms (“ERs”). The report concluded that, after alleged months of investigation, the Company’s ERs routinely treated lower acuity patients at urgent care facilities and excessively billed them for the services rendered.
In response to the airing of the KUSA investigative report, Adeptus’s share price fell from $59.87 per share on November 16, 2015 to a closing price of $46.50 on November 17, 2015—a $13.37 or a 22.3% drop. Furthermore, the stock price has continued to decline since the SPO.
Request more information now by clicking here: www.faruqilaw.com/ADPT. There is no cost or obligation to you.
Take Action
If you invested in Adeptus common stock during the Class Period and would like to discuss your legal rights, visit www.faruqilaw.com/ADPT. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Adeptus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. [email protected] Telephone: (877) 247-4292 or (212) 983-9330


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



